Optimize Financial Inc Takes $208,000 Position in LivaNova PLC (NASDAQ:LIVN)

Optimize Financial Inc purchased a new position in LivaNova PLC (NASDAQ:LIVN) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 4,490 shares of the company’s stock, valued at approximately $208,000.

Several other institutional investors also recently bought and sold shares of LIVN. Sterling Capital Management LLC lifted its stake in shares of LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after buying an additional 1,441 shares in the last quarter. Kennedy Capital Management LLC raised its holdings in LivaNova by 9.2% in the 4th quarter. Kennedy Capital Management LLC now owns 285,708 shares of the company’s stock worth $13,231,000 after acquiring an additional 24,068 shares during the last quarter. LSV Asset Management bought a new position in LivaNova in the 4th quarter valued at approximately $5,367,000. F M Investments LLC purchased a new stake in LivaNova during the 4th quarter valued at $2,687,000. Finally, Martingale Asset Management L P increased its holdings in shares of LivaNova by 109.3% in the 4th quarter. Martingale Asset Management L P now owns 24,561 shares of the company’s stock worth $1,137,000 after purchasing an additional 12,826 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Stock Down 0.5 %

LIVN opened at $33.96 on Monday. The firm’s 50 day simple moving average is $41.37 and its two-hundred day simple moving average is $47.28. The company has a market capitalization of $1.85 billion, a PE ratio of 80.86 and a beta of 0.90. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $64.48. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price objective on shares of LivaNova in a research report on Monday, March 17th. StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 25th. Wolfe Research downgraded shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Mizuho cut their target price on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Finally, Barclays lowered their price target on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $61.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.